Stereotaxis, Inc.

Listed Company

STXSCIK 0001289340NYSENon-AcceleratedSmaller ReportingElectromedical & Electrotherapeutic ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$32.38M

Net Income

$-21.64M

Total Assets

—

Equity

—

Shares Out

97.74M

Op. Cash Flow

$-13.69M

Business

Stereotaxis, Inc. designs, manufactures and markets robotic systems, instruments and integrated information solutions for the interventional laboratory based on its Robotic Magnetic Navigation technology. Its main products and services include the Genesis RMN and GenesisX RMN systems, the Odyssey information and visualization solution (including Odyssey Cinema), disposable interventional devices and catheter portfolios such as Map-iT, bundled x‑ray systems, software and maintenance services. Key business segments comprise robotic magnetic navigation systems, the Odyssey solution, disposables/accessories and recurring service/software revenue. The company sells globally, primarily in the U.S., Europe, China and other international markets through a direct sales force, distributors and strategic partnerships.

Summary from filing dated 2025-03-14

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	32	27	27	28	35
Total cost of revenue	15	12	12	10	12
Gross margin	17	15	15	18	23
Research and development	9	10	10	11	10
Sales and marketing	12	12	12	12	12
General and administrative	18	17	14	14	14
Other	−492,000	—	—	—	—
Total operating expenses	39	39	37	37	36
Operating loss	−22	−25	−22	−19	−13
Other income	2,000	—	30,000	—	—
Interest income, net	500,000	700,000	1	500,000	−11,000
Net loss	−22	−24	−21	−18	−11
Cumulative dividend on convertible preferred stock	−1	−1	−1	−1	−1
Net loss attributable to common stockholders	−23	−25	−22	−20	−12
Basic (per share)	−0.25	−0.3	−0.27	−0.26	−0.16
Diluted (per share)	−0.25	−0.3	−0.27	−0.26	−0.16
Basic (shares)	91	85	81	76	76
Diluted (shares)	91	85	81	76	76

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	13	12	20	9	39
Restricted cash - current	—	219,000	525,000	525,000	453,000
Accounts receivable, net of allowance of $541 and $582 at 2025 and 2024, respectively	6	4	4	5	5
Insurance receivable	4	—	—	—	—
Inventories, net	10	8	8	8	4
Prepaid expenses and other current assets	698,000	2	676,000	1	2
Total current assets	34	26	33	43	51
Property and equipment, net	3	4	3	4	3
Goodwill	4	4	—	—	—
Intangible assets, net	6	7	—	—	—
Operating lease right-of-use assets	5	5	5	5	6
Prepaid and other non-current assets	278,000	107,000	137,000	208,000	278,000
Total assets	52	47	42	53	61
Accounts payable	5	6	3	3	4
Accrued liabilities	2	3	3	3	3
Accrued legal liabilities	4	—	—	—	—
Deferred revenue	6	7	7	7	6
Current contingent consideration	5	6	—	—	—
Current portion of operating lease liabilities	642,000	570,000	428,000	373,000	268,000
Total current liabilities	22	22	13	14	13
Long-term deferred revenue	555,000	2	2	2	2
Long term contingent consideration	5	6	—	—	—
Operating lease liabilities	5	5	5	5	6
Other liabilities	1	64,000	43,000	51,000	218,000
Total liabilities	34	35	20	21	22
Convertible preferred stock, Series A, par value $0.001; 10,000,000 shares authorized; 21,008 and 21,458 shares outstanding at 2025 and 2024, respectively	5	5	6	6	6
Common stock, par value $0.001; 300,000,000 shares authorized, 95,339,628 and 85,326,557 shares issued at 2025 and 2024, respectively	95,000	85,000	81,000	75,000	75,000
Additional paid in capital	597	568	554	543	533
Treasury stock, 4,015 shares at 2025 and 2024	−206,000	−206,000	−206,000	−206,000	−206,000
Accumulated deficit	−583	−562	−538	−517	−499
Total stockholders equity	13	6	16	26	34
Total liabilities and stockholders equity	52	47	42	53	61

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	626,000	587,000	595,000	429,000	106,000
Amortization of intangibles	900,000	400,000	—	—	—
Loss on revaluation of contingent consideration	2	2	—	—	—
Non-cash lease expense	1,000	14,000	—	—	3
Stock-based compensation	10	10	11	11	9
Accounts receivable	−2	691,000	1	316,000	−2
Inventories	−1	677,000	−550,000	−3	−1
Prepaid expenses and other current assets	1	−146,000	649,000	1	−640,000
Other assets	−170,000	29,000	71,000	70,000	30,000
Accounts payable	−880,000	758,000	218,000	−169,000	1
Accrued liabilities	188,000	−99,000	−334,000	−267,000	−681,000
Deferred revenue	−3	574,000	−702,000	989,000	3
Other liabilities	−13,000	21,000	−8,000	−167,000	87,000
Net cash used in operating activities	−14	−8	−9	−8	−3
Purchase of property and equipment	−93,000	−34,000	−366,000	−2	−1
Cash acquired in business acquisitions	—	108,000	—	—	—
Net cash (used in) provided by investing activities	−93,000	74,000	20	−22	−1
Proceeds from issuance of stock	16	297,000	81,000	220,000	547,000
Equity issuance costs	−893,000	—	—	—	—
Net cash provided by financing activities	15	297,000	81,000	220,000	547,000
Net increase (decrease) in cash, cash equivalents, and restricted cash	985,000	−8	11	−30	−4
Fair value of shares of common stock issued for contingent consideration earnouts	4	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro